基于肠-肝轴理论探讨韦荣球菌属与肝脏疾病关系的研究进展

doi:10.12114/j.issn.1007-9572.2024.0310

中国全科医学 ›› 2026, Vol. 29 ›› Issue (11): 1488-1496.DOI: 10.12114/j.issn.1007-9572.2024.0310

• 综述与专论 • 上一篇

基于肠-肝轴理论探讨韦荣球菌属与肝脏疾病关系的研究进展

施雨峰¹, 卢晨霞²^,³^,⁴, 吕安淇¹, 李晓东¹^,²^,³^,⁴^,^*()

1．430065　湖北省武汉市，湖北中医药大学中医学院
2．430061　湖北省武汉市，湖北省中医院肝病研究所　中医肝肾研究及应用湖北省重点实验室
3．430061　湖北省武汉市，湖北时珍实验室
4．430061　湖北省武汉市，湖北中医药大学附属医院

收稿日期:2024-07-10 修回日期:2024-09-05 出版日期:2026-04-15 发布日期:2026-03-12
通讯作者: 李晓东
作者贡献：
施雨峰负责文章的构思与设计、研究资料的收集与整理、论文撰写；卢晨霞负责拟订写作思路以及修订审校；吕安淇负责研究资料的收集与整理、论文修订；李晓东负责指导撰写论文并最后定稿。
基金资助:
国家自然科学基金资助项目(82274352); 湖北省自然科学基金创新群体项目(2020CFA023); 湖北省自然科学基金资助项目(2023AFB426，2023AFD129，2023AFD178)

Research Progress on the Relationship between Veillonella and Liver Diseases Based on the Theory of Intestinal-hepatic Axis

SHI Yufeng¹, LU Chenxia²^,³^,⁴, LYU Anqi¹, LI Xiaodong¹^,²^,³^,⁴^,^*()

1. College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China
2. Institute of Liver Diseases, Hubei Key Laboratory of Theoretical and Applied Research of Liver and Kidney in Traditional Chinese Medicine/Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, China
3. Hubei Shizhen Laboratory, Wuhan 430061, China
4. Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan 430061, China

Received:2024-07-10 Revised:2024-09-05 Published:2026-04-15 Online:2026-03-12
Contact: LI Xiaodong

分享到

摘要/Abstract

摘要： 韦荣球菌属（Veillonella）作为肠道微生物群落的重要成员，其与肝脏疾病之间的关联逐渐受到研究者的关注。尽管已有研究指出Veillonella在肝脏疾病中可能发挥的作用，但目前尚缺乏对这一领域研究成果的有效整合。本文系统地探讨了Veillonella与肝脏疾病的关系，包括其在不同肝脏疾病中的分布特征、影响肝脏健康的潜在机制，以及通过肠-肝轴的作用途径。通过文献综述，本文总结了Veillonella在代谢相关脂肪性肝病、自身免疫性肝病、肝硬化和原发性肝癌中的富集现象，并探讨了其可能通过激活炎症反应、影响肠道屏障功能和促进代谢产物易位等方式影响肝脏健康。研究表明，Veillonella的富集可能与肝脏疾病的发生和发展密切相关，但其具体作用机制仍需进一步研究。本文为理解和利用Veillonella预防和治疗肝脏疾病提供了理论基础，并为未来的研究和临床治疗策略提供了参考。

关键词: 肝脏疾病, 韦荣球菌属, 肠-肝轴, 肠道微生物群, 综述

Abstract:

As an important member of the intestinal microbial community, the relationship between Veillonella and liver diseases has gradually attracted the attention of researchers. Although studies have pointed out the possible role of Veillonella in liver diseases, there is still a lack of effective integration of research results in this field. This article systematically explored the relationship between Veillonella and liver diseases, including its distribution characteristics in different liver diseases, potential mechanisms affecting liver health, and pathways through the gut-liver axis. Through literature review, this paper summarized the enrichment of Veillonella in metabolic-related fatty liver disease, autoimmune liver disease, cirrhosis and primary liver cancer, and discussed its possible effects on liver health by activating inflammatory response, affecting intestinal barrier function and promoting metabolite translocation. Studies had shown that the enrichment of Veillonella may be closely related to the occurrence and development of liver diseases, but its specific mechanism of action still needed further study. This article provided a theoretical basis for understanding and utilizing Veillonella in the prevention and treatment of liver diseases, and provided a reference for future research directions and clinical treatment strategies.

Key words: Liver disease, Veillonella, Intestine-hepatic axis, Intestinal microbiota, Review

中图分类号:

R 57

施雨峰,卢晨霞,吕安淇,等. 基于肠-肝轴理论探讨韦荣球菌属与肝脏疾病关系的研究进展[J]. 中国全科医学, 2026, 29(11): 1488-1496. DOI: 10.12114/j.issn.1007-9572.2024.0310.
SHI Yufeng,LU Chenxia,LYU Anqi, et al. Research Progress on the Relationship between Veillonella and Liver Diseases Based on the Theory of Intestinal-hepatic Axis[J]. Chinese General Practice, 2026, 29(11): 1488-1496. DOI: 10.12114/j.issn.1007-9572.2024.0310.

图/表 1

参考文献 78

[1]	LIU X, CHEN Y, ZHANG S, et al. Gut microbiota-mediated immunomodulation in tumor[J]. J Exp Clin Cancer Res, 2021, 40(1): 221. DOI: 10.1186/s13046-021-01983-x.
[2]	HSU C L, SCHNABL B. The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol, 2023, 21(11): 719-733.
[3]	ROJAS-TAPIAS D F, BROWN E M, TEMPLE E R, et al. Inflammation-associated nitrate facilitates ectopic colonization of oral bacterium Veillonella parvula in the intestine[J]. Nat Microbiol, 2022, 7(10): 1673-1685. DOI: 10.1038/s41564-022-01224-7.
[4]	ZHAI Q L, WU H Y, ZHENG S Y, et al. Association between gut microbiota and NAFLD/NASH: a bidirectional two-sample Mendelian randomization study[J]. Front Cell Infect Microbiol, 2023, 13: 1294826. DOI: 10.3389/fcimb.2023.1294826.
[5]	MAYNERIS-PERXACHS J, CARDELLINI M, HOYLES L, et al. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome[J]. Microbiome, 2021, 9(1): 104. DOI: 10.1186/s40168-021-01052-7.
[6]	YAMAMOTO K, HONDA T, INUKAI Y, et al. Identification of the microbiome associated with prognosis in patients with chronic liver disease[J]. Microorganisms, 2024, 12(3): 610. DOI: 10.3390/microorganisms12030610.
[7]	TILG H, ADOLPH T E, TRAUNER M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab, 2022, 34(11): 1700-1718. DOI: 10.1016/j.cmet.2022.09.017.
[8]	PABST O, HORNEF M W, SCHAAP F G, et al. Gut–liver axis: barriers and functional circuits[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(7): 447-461. DOI: 10.1038/s41575-023-00771-6.
[9]	MASHIMA I, NAKAZAWA F. The interaction between Streptococcus spp. and Veillonella tobetsuensis in the early stages of oral biofilm formation[J]. J Bacteriol, 2015, 197(3): 2104-2111. DOI: 10.1128/JB.02512-14.
[10]	MASHIMA I, LIAO Y C, MIYAKAWA H, et al. Veillonella infantium sp. nov., an anaerobic, Gram-stain-negative coccus isolated from tongue biofilm of a Thai child[J]. Int J Syst Evol Microbiol, 2018, 68(4): 1101-1106. DOI: 10.1099/ijsem.0.002632.
[11]	DJAIS A A, THEODOREA C F, MASHIMA I, et al. Identification and phylogenetic analysis of oral Veillonella species isolated from the saliva of Japanese children[J]. F1000Research, 2019, 8: 616. DOI: 10.12688/f1000research.18506.5.
[12]	KOLENBRANDER P. The genus veillonella[M]//DWORKIN M, FALKOW S, ROSENBERG E, et al. The prokaryotes: a handbook on the biology of bacteria. 3rd ed. New York: Springer, 1992: 1022-1040.
[13]	CHANG X X, CHEN Y F, CUI D X, et al. Propionate-producing Veillonella parvula regulates the malignant properties of tumor cells of OSCC[J]. Med Oncol, 2023, 40(3): 98.
[14]	SCHEIMAN J, LUBER J M, CHAVKIN T A, et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism[J]. Nat Med, 2019, 25(7): 1104-1109. DOI: 10.1038/s41591-019-0485-4.
[15]	MA S, ZHANG F, ZHOU F, et al. Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19[J]. Signal Transduct Target Ther, 2021, 6(1): 191
[16]	CHEN X, LI P, LIU M, et al. Gut dysbiosis induces the development of pre-eclampsia through bacterial translocation[J]. Gut, 2020, 69(3): 513-522. DOI: 10.1136/gutjnl-2019-319101.
[17]	MA X Y, KIM J K, SHIN Y J, et al. Lipopolysaccharide-producing Veillonella infantium and Escherichia fergusonii cause vagus nerve-mediated cognitive impairment in mice[J]. Brain Behav Immun, 2024, 118: 136-148. DOI: 10.1016/j.bbi.2024.02.031.
[18]	YOUNOSSI Z M. Non-alcoholic fatty liver disease-a global public health perspective[J]. J Hepatol, 2019, 70(3): 531-544.
[19]	LANG S, SCHNABL B. Microbiota and fatty liver disease-the known, the unknown, and the future[J]. Cell Host Microbe, 2020, 28(2): 233-244. DOI: 10.1016/j.chom.2020.07.007.
[20]	MOHAMMADI Z, POUSTCHI H, HEKMATDOOST A, et al. Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis[J]. J Res Med Sci, 2022, 27: 54. DOI: 10.4103/jrms.jrms_673_21.
[21]	LI F, SUN G, WANG Z K, et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients[J]. Sci China Life Sci, 2018, 61(7): 770-778. DOI: 10.1007/s11427-017-9303-9.
[22]	DEMIR M, LANG S, MARTIN A, et al. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?[J]. J Gastroenterol Hepatol, 2020, 35(11): 1969-1977. DOI: 10.1111/jgh.15071.
[23]	LIANG Y J, LIANG S, ZHANG Y P, et al. Oral administration of compound probiotics ameliorates HFD-induced gut microbe dysbiosis and chronic metabolic inflammation via the G protein-coupled receptor 43 in non-alcoholic fatty liver disease rats[J]. Probiotics Antimicrob Proteins, 2019, 11(1): 175-185. DOI: 10.1007/s12602-017-9378-3.
[24]	LI W F, YANG H Y, ZHAO Q, et al. Polyphenol-rich loquat fruit extract prevents fructose-induced nonalcoholic fatty liver disease by modulating glycometabolism, lipometabolism, oxidative stress, inflammation, intestinal barrier, and gut microbiota in mice[J]. J Agric Food Chem, 2019, 67(27): 7726-7737. DOI: 10.1021/acs.jafc.9b02523.
[25]	ZHAO F, DONG T, YUAN K Y, et al. Shifts in the bacterial community of supragingival plaque associated with metabolic-associated fatty liver disease[J]. Front Cell Infect Microbiol, 2020, 10: 581888. DOI: 10.3389/fcimb.2020.581888.
[26]	LOOMBA R, LING L, DINH D M, et al. The commensal microbe Veillonella as a marker for response to an FGF19 analog in NASH[J]. Hepatology, 2021, 73(1): 126-143. DOI: 10.1002/hep.31523.
[27]	ZHENG Y P, RAN Y, ZHANG H X, et al. The microbiome in autoimmune liver diseases: metagenomic and metabolomic changes[J]. Front Physiol, 2021, 12: 715852.
[28]	WANG R, TANG R Q, LI B, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cell Mol Immunol, 2021, 18(1): 4-17. DOI: 10.1038/s41423-020-00592-6.
[29]	WEI Y, LI Y, YAN L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3): 569-577. DOI: 10.1136/gutjnl-2018-317836.
[30]	LIWINSKI T, CASAR C, RUEHLEMANN M C, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51(12): 1417-1428. DOI: 10.1111/apt.15754.
[31]	ELSHERBINY N M, RAMMADAN M, HASSAN E A, et al. Autoimmune hepatitis: shifts in gut microbiota and metabolic pathways among Egyptian patients[J]. Microorganisms, 2020, 8(7): 1011. DOI: 10.3390/microorganisms8071011.
[32]	LOU J M, JIANG Y, RAO B C, et al. Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals[J]. Front Cell Infect Microbiol, 2020, 10: 342. DOI: 10.3389/fcimb.2020.00342.
[33]	CHEN W H, WEI Y R, XIONG A Z, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58(1): 25-38. DOI: 10.1007/s12016-019-08731-2.
[34]	TANG R, WEI Y, LI Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3): 534-541. DOI: 10.1136/gutjnl-2016-313332.
[35]	KUMMEN M, HOLM K, ANMARKRUD J A, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls[J]. Gut, 2017, 66(4): 611-619. DOI: 10.1136/gutjnl-2015-310500.
[36]	VIEIRA-SILVA S, SABINO J, VALLES-COLOMER M, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses[J]. Nat Microbiol, 2019, 4(11): 1826-1831. DOI: 10.1038/s41564-019-0483-9.
[37]	BAJER L, KVERKA M, KOSTOVCIK M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis[J]. World J Gastroenterol, 2017, 23(25): 4548-4558. DOI: 10.3748/wjg.v23.i25.4548.
[38]	LAPIDOT Y, AMIR A, BEN-SIMON S, et al. Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis[J]. Hepatol Int, 2021, 15(1): 191-201.
[39]	CORTEZ R V, MOREIRA L N, PADILHA M, et al. Gut microbiome of children and adolescents with primary sclerosing cholangitis in association with ulcerative colitis[J]. Front Immunol, 2021, 11: 598152. DOI: 10.3389/fimmu.2020.598152.
[40]	SABINO J, VIEIRA-SILVA S, MACHIELS K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J]. Gut, 2016, 65(10): 1681-1689. DOI: 10.1136/gutjnl-2015-311004.
[41]	ABE K, TAKAHASHI A, FUJITA M, et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease[J]. PLoS One, 2018, 13(7): e0198757. DOI: 10.1371/journal.pone.0198757.
[42]	RAO B, LOU J, LU H, et al. Oral microbiome characteristics in patients with autoimmune hepatitis[J]. Front Cell Infect Microbiol, 2021, 11: 656674. DOI: 10.3389/fcimb.2021.656674.
[43]	LV L X, JIANG H Y, CHEN X X, et al. The salivary microbiota of patients with primary biliary cholangitis is distinctive and pathogenic[J]. Front Immunol, 2021, 12: 713647.
[44]	TREBICKA J, MACNAUGHTAN J, SCHNABL B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol, 2021, 75(Suppl 1): S67-81. DOI: 10.1016/j.jhep.2020.11.013.
[45]	BAJAJ J S, KHORUTS A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis[J]. J Hepatol, 2020, 72(5): 1003-1027. DOI: 10.1016/j.jhep.2020.01.017.
[46]	QIN N, YANG F L, LI A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513: 59-64. DOI: 10.1038/nature13568.
[47]	SHAO L, LING Z, CHEN D, et al. Disorganized gut microbiome contributed to liver cirrhosis progression: a meta-omics-based study[J]. Front Microbiol, 2018, 9: 3166. DOI: 10.3389/fmicb.2018.03166.
[48]	DENG Y D, PENG X B, ZHAO R R, et al. The intestinal microbial community dissimilarity in hepatitis B virus-related liver cirrhosis patients with and without at alcohol consumption[J]. Gut Pathog, 2019, 11: 58. DOI: 10.1186/s13099-019-0337-2.
[49]	WU Z, ZHOU H, LIU D, et al. Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis[J]. Front Cell Infect Microbiol, 2023, 13: 1218552. DOI: 10.3389/fcimb.2023.1218552.
[50]	HÖPPNER J, KROHN S, VAN DEN MUNCKHOF E H A, et al. Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites[J]. Sci Rep, 2023, 13(1): 23001. DOI: 10.1038/s41598-023-49505-3.
[51]	HUANG C Y, ZHANG H P, HAN W J, et al. Disease predisposition of human leukocyte antigen class Ⅱ genes influences the gut microbiota composition in patients with primary biliary cholangitis[J]. Front Immunol, 2022, 13: 984697. DOI: 10.3389/fimmu.2022.984697.
[52]	JIN Y, SHI M, FENG J, et al. Splenectomy ameliorates liver cirrhosis by restoring the gut microbiota balance[J]. Cell Mol Life Sci, 2024, 81(1): 32. DOI: 10.1007/s00018-023-05055-5.
[53]	SUNG C M, LIN Y F, CHEN K F, et al. Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome[J]. Cell Mol Gastroenterol Hepatol, 2019, 8(2): 301-318.e2. DOI: 10.1016/j.jcmgh.2019.04.008.
[54]	PATEL V C, LEE S, MCPHAIL M J W, et al. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial[J]. J Hepatol, 2022, 76(2): 332-342. DOI: 10.1016/j.jhep.2021.09.010.
[55]	ENOMOTO M, KAJI K, NISHIMURA N, et al. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis[J]. Dig Liver Dis, 2022, 54(10): 1392-1402. DOI: 10.1016/j.dld.2022.04.012.
[56]	ZHAO Y, ZHAO M, ZHANG Y, et al. Bile acids metabolism involved in the beneficial effects of Danggui Shaoyao San via gut microbiota in the treatment of CCl4 induced hepatic fibrosis[J]. J Ethnopharmacol, 2024, 319(Pt 3): 117383. DOI: 10.1016/j.jep.2023.117383.
[57]	ALIWA B, HORVATH A, TRAUB J, et al. Altered gut microbiome, bile acid composition and metabolome in sarcopenia in liver cirrhosis[J]. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2676-2691.
[58]	CHEN Y, JI F, GUO J, et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology[J]. Sci Rep, 2016, 6: 34055. DOI: 10.1038/srep34055.
[59]	YU L X, SCHWABE R F. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539. DOI: 10.1038/nrgastro.2017.72.
[60]	TRIPATHI A, DEBELIUS J, BRENNER D A, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411.
[61]	MAEDA S, KAMATA H, LUO J L, et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis[J]. Cell, 2005, 121(7): 977-990.
[62]	ZHANG W Z, XU X S, CAI L P, et al. Dysbiosis of the gut microbiome in elderly patients with hepatocellular carcinoma[J]. Sci Rep, 2023, 13(1): 7797. DOI: 10.1038/s41598-023-34765-w.
[63]	FENG J, WU Y, DAI P, et al. Gut microbial signatures of patients with primary hepatocellular carcinoma and their healthy first-degree relatives[J]. J Appl Microbiol, 2023, 134(10): lxad221. DOI: 10.1093/jambio/lxad221.
[64]	POMYEN Y, CHAISAINGMONGKOL J, RABIBHADANA S, et al. Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma[J]. Sci Rep, 2023, 13(1): 11406. DOI: 10.1038/s41598-023-38307-2.
[65]	DENG T, LI J L, HE B J, et al. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer[J]. Hepatol Int, 2022, 16(1): 99-111.
[66]	ZHANG L, WU Y N, CHEN T, et al. Relationship between intestinal microbial dysbiosis and primary liver cancer[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(2): 149-157. DOI: 10.1016/j.hbpd.2019.01.002.
[67]	TANG Y, ZHOU H, XIANG Y, et al. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol, 2021, 33(1S Suppl 1): e167-175. DOI: 10.1097/MEG.0000000000001978.
[68]	ZHENG C, LU F, CHEN B, et al. Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma[J]. Cancer Sci, 2023, 114(12): 4717-4731.
[69]	XU W, JIANG Y, TAO J, et al. Correlation analysis for alterations of intestinal flora in hepatocellular carcinoma patients: combinatorial detection of Coriobacterium, Atopobium, Coprococcus and Veillonella dispar may be a new method for HCC diagnosis[J]. J Med Microbiol, 2023, 72(6). DOI: 10.1099/jmm.0.001713.
[70]	CHUNG M W, KIM M J, WON E J, et al. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients[J]. World J Gastroenterol, 2021, 27(42): 7340-7349. DOI: 10.3748/wjg.v27.i42.7340.
[71]	LEE P C, WU C J, HUNG Y W, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2022, 10(6): e004779. DOI: 10.1136/jitc-2022-004779.
[72]	PONZIANI F R, DE LUCA A, PICCA A, et al. Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma[J]. Hepatol Commun, 2022, 6(6): 1492-1501. DOI: 10.1002/hep4.1905.
[73]	RAO B C, ZHANG G Z, ZOU Y W, et al. Alterations in the human oral microbiome in cholangiocarcinoma[J]. Mil Med Res, 2022, 9(1): 62. DOI: 10.1186/s40779-022-00423-x.
[74]	YANG X, MAI H, ZHOU J, et al. Alterations of the gut microbiota associated with the occurrence and progression of viral hepatitis[J]. Front Cell Infect Microbiol, 2023, 13: 1119875.
[75]	CHEN Z, XIE Y, ZHOU F, et al. Featured gut microbiomes associated with the progression of chronic hepatitis B disease[J]. Front Microbiol 2020, 11: 383. DOI: 10.3389/fmicb.2020.00383.
[76]	LANG S, FAIRFIED B, GAO B, et al. Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients[J]. Gut Microbes, 2020, 12(1): 1785251.
[77]	KIM S S, EUN J W, CHO H J, et al. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis[J]. Aliment Pharmacol Ther, 2021, 53(4): 540-551.
[78]	HE K N, LIU M M, WANG Q, et al. Combined analysis of 16S rDNA sequencing and metabolomics to find biomarkers of drug-induced liver injury[J]. Sci Rep, 2023, 13(1): 15138.

基于肠-肝轴理论探讨韦荣球菌属与肝脏疾病关系的研究进展

Research Progress on the Relationship between Veillonella and Liver Diseases Based on the Theory of Intestinal-hepatic Axis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 78

相关文章 15

编辑推荐

Metrics

留言

[1]	叶鑫瑛, 殷安康, 刘定岭, 吕翔, 王逸. 按病种分值付费支付模式下综合医院全科医学科发展研究[J]. 中国全科医学, 2026, 29(11): 1378-1384.
[2]	孙宇辰, 石雅馨, 师伟. 经血源性干细胞联合补肾活血类中药治疗子宫内膜功能减退类疾病的研究进展[J]. 中国全科医学, 2026, 29(11): 1481-1487.
[3]	葛奥淇, 高欣怡, 李佳威, 李娟娟, 袁蓓蓓. 基层医务人员慢性病健康行为管理能力的培训干预及其效果：系统综述及Meta分析[J]. 中国全科医学, 2026, 29(09): 1109-1120.
[4]	王晨瑜, 王晓艳, 张立秀, 王丽娜. 轻度认知障碍人群社区筛查与诊断管理策略的研究进展[J]. 中国全科医学, 2026, 29(08): 1037-1043.
[5]	严明, 夏瑀, 周鹏翔, 周馨媚, 方力争, 赵洋, 徐志杰. 处方精简实施的阻碍因素和促进因素：基于更新版实施性研究综合框架的范围综述[J]. 中国全科医学, 2026, 29(07): 936-944.
[6]	项天乐, 周娜, 李芳, 曹梅娟. 儿童24 h活动行为测评方法研究进展[J]. 中国全科医学, 2026, 29(06): 760-766.
[7]	王立娜, 雷警输, 李奎宝, 王睿颖, 李新苗, 王芳芳, 郭晓荣, 牛瑞浩, 赵伟, 周芳芳, 赵京晶, 李忠佑. 急性心肌梗死患者炎症反应研究进展[J]. 中国全科医学, 2026, 29(06): 790-801.
[8]	罗秀, 麻钊丽, 黄梦宇, 任茜. 肠道微生物群对代谢综合征的遗传预测因果效应研究[J]. 中国全科医学, 2026, 29(05): 612-622.
[9]	史佳琦, 王玉欣, 罗佳妮, 姜琪, 吴善玉, 金头峰. 胃肠道癌症患者症状群影响因素的范围综述[J]. 中国全科医学, 2026, 29(05): 668-675.
[10]	田紫薇, 杨支兰, 赵慧敏, 翟艳萍, 李鸿雁, 杜淼, 晋源媛, 宋泽雨. 膝骨关节炎患者衰弱研究的范围综述[J]. 中国全科医学, 2026, 29(05): 676-680.
[11]	曹新阳, 汪洋, 金花, 于德华, 杨辉, 刘晓云, 许岩丽. 全科医学科研能力发展的影响因素：一项范围综述[J]. 中国全科医学, 2026, 29(04): 444-456.
[12]	王艺衡, 许晓明, 夏云龙, 夏林莺, 韩雪, 郭永珍, 刘泉池, 闫文俊. 射血分数保留的心力衰竭药物治疗进展[J]. 中国全科医学, 2026, 29(03): 403-408.
[13]	刘燕, 袁艳玲, 令榕, 王兰云, 孙丽. 远程医疗在冠心病患者心脏康复中应用的范围综述[J]. 中国全科医学, 2025, 28(36): 4640-4647.
[14]	王怡, 程金湘, 赵显超, 任佳封, 张丽萍, 董孟龙, 林志烽, 宿长军. 药物相关的快速眼动睡眠行为障碍研究新进展[J]. 中国全科医学, 2025, 28(35): 4511-4516.
[15]	李明月, 汤皓晴, 郑汇娴, 张笑天, 刘晓云. 基本卫生保健质量概念内涵研究的系统综述[J]. 中国全科医学, 2025, 28(34): 4300-4310.